• An innovative biotech company with around 100 employees, and with headquarters
    in Freiburg as well as a sales office in the US.


  • A leading manufacturer of high-quality biological reagents for the growing cell and
    gene therapy and regenerative medicine markets.


  • Our customers are multinational pharmaceutical companies, innovative life science
    startups, and research institutes.


  • As of July 2021, we belong to the Sartorius Group, a publicly traded international
    pharmaceutical and laboratory supplier based in Göttingen. In the coming years, our
    headquarters in Freiburg will continue to expand.


Discover our vacancies on the Sartorius central career page.


In Freiburg, we develop, produce, and market human cytokines and growth factors as well as serum-free cell culture media that are GMP-compliant. We currently offer our customers more than 40 different products and have many more in the pipeline. Our products are used for the manufacture of life-saving medicines, including for a novel and highly effective immunotherapy for certain forms of leukemia (medications for cancer therapy; Advanced Therapy Medicinal Products/ATMP). These products enable us to help people who previously had little to no chance of being cured.

Emily’s Story– New Treatment Strategies Through Cell and Gene Therapy

In the past decades, the standard therapy for cancer treatments has consisted of surgery, chemotherapy, and radiation. None of these treatments were effective for Emily, who was diagnosed with acute lymphocytic leukemia (ALL) at the age of five. Intent on finding a cure, her parents admitted her into a CAR-T cell therapy, which made her the first child in the world to participate in a phase one study. T cells from her own blood were collected and genetically reprogrammed to express a chimeric antigen receptor (CAR). These modified immune cells recognized and attacked Emily’s tumor cells. She has now been cancer-free for over ten years.

We are proud that our products help to accelerate the development of novel therapeutics for cell and gene therapy and that we contribute to the increased safety and efficiency in the way these products are manufactured. As a dynamic, growing company, we are looking for people who share our ambition and want to apply their talent in a fast-changing, innovative environment.

Felicia M Rosenthal, Managing Director, Sartorius CellGenix GmbH

Felicia M Rosenthal


We love Freiburg and enjoy living and working in the Tuscany of Germany.

Freiburg im Breisgau, the sunny city in the Black Forest, is Germany’s southernmost major city. With 240,000 inhabitants, the city is large enough to offer all the amenities of a big city while small enough to be easily bikeable.

It is the gateway to the Black Forest and only a stone’s throw from the sun-drenched vineyards of Kaiserstuhl and Markgräflerland. The excellent quality of life, mild climate, diverse recreational activities, abundant culinary delicacies, strong commitment to sustainability (“Green City”), and, last but not least, the close proximity to France and Switzerland with its life science hub Basel — all of this makes Freiburg an ideal place to live!


The basics

  • 40-hour work week
  • Flexible working hours
  • 30 vacation days per year
  • The opportunity to work from home (when possible)
  • Part-time work
  • Open-ended employment contracts (generally)
  • Individual training from day one
  • Opportunities for professional development (both internal and external)

The extras

  • Employer contribution to the company pension plan (up to 20%) and discounted fitness offers (Hansefit)
  • Modern IT equipment
  • Flat hierarchy with short decision-making processes
  • Complementary beverages (coffee, tea, water)
  • Company physician
  • Summer party and Christmas celebration
  • Free on-site parking
  • Easy access to public transportation
  • Ample bicycle parking


It took nearly 20 years of developing the concept of gene therapy before the first gene therapy procedure was performed in 1990. Then, in 1994, our company was founded as a university clinic spin-off. Within that first year, we were granted permission to manufacture blood  stem cells. Since then, we have manufactured more than 10,000 cell products and developed a vaccine that was part of a clinical trial.  Thanks to this extensive experience, we have become leading experts in raw materials (cytokines, growth factors, and cell culture media).


No position that’s right for you at the moment?